BioMarin Pharmaceutical (BMRN) : During the past 4 weeks, traders have been relatively bearish on BioMarin Pharmaceutical (BMRN), hence the stock is down -2.07% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.46% relative to the S&P 500. The 4-week change in the price of the stock is -1.7% and the stock has fallen -0.49% in the past 1 week.
BioMarin Pharmaceutical Inc. is up 6.41% in the last 3-month period. Year-to-Date the stock performance stands at -12.19%. The stock has recorded a 20-day Moving Average of 3.94% and the 50-Day Moving Average is 3.5%.
BioMarin Pharmaceutical (NASDAQ:BMRN): The stock opened at $93.07 on Friday but the bulls could not build on the opening and the stock topped out at $93.40 for the day. The stock traded down to $91.76 during the day, due to lack of any buying support eventually closed down at $91.99 with a loss of -1.64% for the day. The stock had closed at $93.52 on the previous day. The total traded volume was 698,638 shares.
Also, Barclays maintains its view on BioMarin Pharmaceutical (NASDAQ:BMRN) according to the research report released by the firm to its investors. The shares have now been rated Overweight by the stock experts at the ratings house. Barclays raises the price target from $105 per share to $125 per share on BioMarin Pharmaceutical . The rating by the firm was issued on August 5, 2016.
BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for serious diseases and medical conditions. The Companys product portfolio is comprised of five approved products and multiple clinical and pre-clinical product candidates. Its approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States, the European Union and subsequently in several other countries. Naglazyme received marketing approval in the United States, the European Union and subsequently in other countries. Kuvan was granted marketing approval in the United States, the European Union. Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), was approved for marketing in the United States, the European Union, and subsequently in other countries. Firdapse was approved by the European Medicines Agency (EMA).